Volume 12 Issue 3
May  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(3): 344-350
Wu Fengdong, Shi Bin. Liver transplantation and comprehensive treatment of intrahepatic cholangiocarcinoma[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 344-350. doi: 10.3969/j.issn.1674-7445.2021.03.014
Citation: Wu Fengdong, Shi Bin. Liver transplantation and comprehensive treatment of intrahepatic cholangiocarcinoma[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 344-350. doi: 10.3969/j.issn.1674-7445.2021.03.014
shu

Liver transplantation and comprehensive treatment of intrahepatic cholangiocarcinoma

doi: 10.3969/j.issn.1674-7445.2021.03.014

  • Department of Organ Transplantation, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China

More Information
  • Corresponding author: Wu Fengdong, Email: 13501080376@163.com
  • Received Date: 2021-02-25
    Available Online: 2021-05-19
  • Publish Date: 2021-05-15
    Abstract
  • Liver transplantation is an effective approach to treat intrahepatic cholangiocarcinoma (ICC). It is necessary to strictly control surgical indications of ICC because of its high invasiveness, lymph node metastasis and recurrence rate after liver transplantation. Liver transplantation yields high efficacy for single ICC with a diameterof ≤2 cm. For advanced ICC, neoadjuvant therapies including locoregional treatment and systemic chemotherapy should be initially delivered. According to the response of these neoadjuvant therapies, whether liver transplantation should be performed can be determined, and individualized adjuvant therapy should be delivered after operation. At present, multiple gene mutation targets and targeted therapeutic drugs for cholangiocarcinoma have been identified. Comprehensive treatment before and after liver transplantation may expand surgical indications of liver transplantation for ICC and improve clinical prognosis of the recipients. In this article, liver transplantation for ICC, neoadjuvant therapy before liver transplantation, postoperative adjuvant therapy and targeted therapy for ICC were reviewed.

     

    • FullText(HTML)
  • loading
    • References(36)
  • [1]
    HAND F, HOTI E. Contemporary role of liver transplantation for the treatment of cholangiocarcinoma[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(6): 475-481. DOI: 10.1080/17474124.2020.1765771.
    [2]
    李斌, 吕凌, 王学浩. 胆管癌的诊治困境与肝移植进展[J]. 器官移植, 2014, 5(5): 328-330. DOI: 10.3969/j.issn.1674-7445.2014.05.015.

    LI B, LYU L, WANG XH. Trouble of diagnosis and treatment of cholangiocarcinoma and progress on liver transplantation[J]. Organ Transplant, 2014, 5(5): 328-330. DOI: 10.3969/j.issn.1674-7445.2014.05.015.
    [3]
    丁义涛. 胆管癌的肝移植治疗策略回顾与展望[J]. 器官移植, 2013, 4(2): 63-67. DOI: 10.3969/j.issn.1674-7445. 2013.02.001.

    DING YT. Retrospect and prospect on the strategy of liver transplantation on cholangiocarcinoma[J]. Organ Transplant, 2013, 4(2): 63-67. DOI: 10.3969/j.issn.1674-7445.2013.02.001.
    [4]
    MARTIN P, DIMARTINI A, FENG S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Hepatology, 2014, 59(3): 1144-1165. DOI: 10.1002/hep.26972.
    [5]
    European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation[J]. J Hepatol, 2016, 64(2): 433-485. DOI: 10.1016/j.jhep.2015. 10.006.
    [6]
    SAPISOCHIN G, FACCIUTO M, RUBBIA-BRANDT L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4): 1178-1188. DOI: 10.1002/hep.28744.
    [7]
    LUNSFORD KE, JAVLE M, HEYNE K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series[J]. Lancet Gastroenterol Hepatol, 2018, 3(5): 337-348. DOI: 10.1016/S2468-1253(18)30045-1.
    [8]
    DE MARTIN E, RAYAR M, GOLSE N, et al. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis[J]. Liver Transpl, 2020, 26(6): 785-798. DOI: 10.1002/lt.25737.
    [9]
    FACCIUTO ME, SINGH MK, LUBEZKY N, et al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation[J]. Transplantation, 2015, 99(1): 151-157. DOI: 10.1097/TP.0000000000000286.
    [10]
    HEIMBACH JK, GORES GJ, HADDOCK MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Semin Liver Dis, 2004, 24(2): 201-207. DOI: 10.1055/s-2004-828896.
    [11]
    HONG JC, JONES CM, DUFFY JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center[J]. Arch Surg, 2011, 146(6): 683-689. DOI: 10.1001/archsurg.2011.116.
    [12]
    WONG M, KIM J, GEORGE B, et al. Downstaging locally advanced cholangiocarcinoma pre-liver transplantation: a prospective pilot study[J]. J Surg Res, 2019, 242: 23-30. DOI: 10.1016/j.jss.2019.04.023.
    [13]
    GOLDARACENA N, GORGEN A, SAPISOCHIN G. Current status of liver transplantation for cholangiocarcinoma[J]. Liver Transpl, 2018, 24(2): 294-303. DOI: 10.1002/lt.24955.
    [14]
    GRINGERI E, GAMBATO M, SAPISOCHIN G, et al. Cholangiocarcinoma as an indication for liver transplantation in the era of transplant oncology[J]. J Clin Med, 2020, 9(5): 1353. DOI: 10.3390/jcm9051353.
    [15]
    MANTEL HT, WESTERKAMP AC, ADAM R, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival[J]. PLoS One, 2016, 11(6): e0156127. DOI: 10.1371/journal.pone.0156127.
    [16]
    LEE DD, CROOME KP, MUSTO KR, et al. Liver transplantation for intrahepatic cholangiocarcinoma[J]. Liver Transpl, 2018, 24(5): 634-644. DOI: 10.1002/lt.25052.
    [17]
    PANJALA C, NGUYEN JH, AL-HAJJAJ AN, et al. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma[J]. Liver Transpl, 2012, 18(5): 594-601. DOI: 10.1002/lt.22462.
    [18]
    PANAYOTOVA GG, PATERNO F, GUARRERA JV, et al. Liver transplantation for cholangiocarcinoma: insights into the prognosis and the evolving indications[J]. Curr Oncol Rep, 2020, 22(5): 49. DOI: 10.1007/s11912-020-00910-1.
    [19]
    RAYAR M, LEVI SANDRI GB, HOUSSEL-DEBRY P, et al. Multimodal therapy including yttrium-90 radioembolization as a bridging therapy to liver transplantation for a huge and locally advanced intrahepatic cholangiocarcinoma[J]. J Gastrointestin Liver Dis, 2016, 25(3): 401-404. DOI: 10.15403/jgld.2014.1121.253.y90.
    [20]
    RIZVI S, KHAN SA, HALLEMEIER CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111. DOI: 10.1038/nrclinonc.2017.157.
    [21]
    TAO R, KRISHNAN S, BHOSALE PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis[J]. J Clin Oncol, 2016, 34(3): 219-226. DOI: 10.1200/JCO.2015.61.3778.
    [22]
    HONG TS, WO JY, YEAP BY, et al. Multi-institutional phase Ⅱ study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. J Clin Oncol, 2016, 34(5): 460-468. DOI: 10.1200/JCO.2015.64.2710.
    [23]
    SAKAMOTO T, TAKEDA Y, OHMURA Y, et al. Treatment outcomes of gemcitabine and cisplatin combination therapy for unresectable and recurrent biliary tract cancer[J]. Gan To Kagaku Ryoho, 2018, 45(13): 2414-2416.
    [24]
    BENSON AB, D'ANGELICA MI, ABBOTT DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019[J]. J Natl Compr Canc Netw, 2019, 17(4): 302-310. DOI: 10.6004/jnccn.2019.0019.
    [25]
    SHROFF RT, JAVLE MM, XIAO L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6): 824-830. DOI: 10.1001/jamaoncol.2019.0270.
    [26]
    SIA D, HOSHIDA Y, VILLANUEVA A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4): 829-840. DOI: 10.1053/j.gastro.2013.01.001.
    [27]
    NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9): 1003-1010. DOI: 10.1038/ng.3375.
    [28]
    ROSS JS, WANG K, GAY L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing[J]. Oncologist, 2014, 19(3): 235-242. DOI: 10.1634/theoncologist.2013-0352.
    [29]
    KATOH M. Fibroblast growth factor receptors as treatment targets in clinical oncology[J]. Nat Rev Clin Oncol, 2019, 16(2): 105-122. DOI: 10.1038/s41571-018-0115-y.
    [30]
    JAVLE M, LOWERY M, SHROFF RT, et al. Phase Ⅱ study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J]. J Clin Oncol, 2018, 36(3): 276-282. DOI: 10.1200/JCO.2017.75.5009.
    [31]
    ABOU-ALFA GK, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684. DOI: 10.1016/S1470-2045(20)30109-1.
    [32]
    MAZZAFERRO V, EL-RAYES BF, DROZ DIT BUSSET M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma[J]. Br J Cancer, 2019, 120(2): 165-171. DOI: 10.1038/s41416-018-0334-0.
    [33]
    TABERNERO J, BAHLEDA R, DIENSTMANN R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors[J]. J Clin Oncol, 2015, 33(30): 3401-3408. DOI: 10.1200/JCO.2014.60.7341.
    [34]
    LOWERY MA, BURRIS HA 3RD, JANKU F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4(9): 711-720. DOI: 10.1016/S2468-1253(19)30189-X.
    [35]
    SUN W, PATEL A, NORMOLLE D, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma[J]. Cancer, 2019, 125(6): 902-909. DOI: 10.1002/cncr.31872.
    [36]
    王葵, 陈秦俊杰, 夏勇, 等. 肝内胆管癌的外科综合治疗[J]. 临床外科杂志, 2019, 27(8): 638-641. DOI: 10.3969/j.issn.1005-6483.2019.08.003.

    WANG K, CHEN QJJ, XIA Y, et al. Comprehensive treatment of surgical for intrahepatic cholangiocarcinoma[J]. J Clin Surg, 2019, 27(8): 638-641. DOI: 10.3969/j.issn.1005-6483.2019.08.003.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (677) PDF downloads(67) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return